UPDATE: Lilly halts work on potential blockbuster cholesterol drug
Eli Lilly shares plunged nearly 10 percent Monday morning after it said it would stop development of evacetrapib, an experimental cholesterol drug with blockbuster potential.
Health Care Businesses
Articles
Lilly expands China drug partnership in growing cancer market
Suzhou, China-based Innovent could receive payments totaling more than $1 billion if the cancer products it develops with Lilly reach certain milestones.
Lilly to add 50 employees at R&D center in New York
The drugmaker is trying to beef up its work on using the immune system to fight cancer. Indianapolis will remain Lilly’s main hub for research and development.
American Senior fires No. 2 executive in wake of FBI raid
American Senior Communities has fired its chief operating officer and accepted the resignation of its chief financial officer—17 days after an FBI raid of its offices and the home of its former CEO James Burkhart.
Puerto Rico plans new corporate tax to replace excise levy
Puerto Rico officials are looking to replace an expiring tax with a new levy to draw much-needed revenue from the world’s best-selling medications while seeking to avoid driving U.S. manufacturers such as Eli Lilly and Co. from the commonwealth.
Lilly stock climbs on positive arthritis drug test
A potential rheumatoid arthritis treatment from drugmakers Eli Lilly and Co. and Incyte Corp. fared better than another drug in late-stage testing, Lilly said Tuesday.
Settlement clears way for Lilly to launch once-a-day insulin
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
Applications to Marian medical school keep rising
With the number of applications to Marian’s College of Osteopathic Medicine running twice as high as initially expected, school leaders say they are confident Marian can help reduce a looming physician shortage in Indiana.
Lilly’s heart study sets up showdown with Novo’s Victoza
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
Group urges Dems to tackle pharmaceutical prices
Pharmaceutical industry members are likely to dislike the proposal, which would require them disclose how much they spend on research and development, production, and sales and marketing.
Jardiance study lifts Lilly shares to 15-year high
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.
Lilly shares jump on latest data from diabetes drug
A diabetes pill called Jardiance sold by Eli Lilly and Co. cut deaths from heart attacks and strokes in thousands of patients, the first drug to show promise in helping subdue two of the world’s most rampant health epidemics.
Senior health care firm operator Trilogy sold in $1.2B deal
Trilogy Health Services LLC, which operates more than 70 senior-living facilities in Indiana, is being acquired. The company has at least 14 properties in central Indiana, including two in Indianapolis.
Drug-price increases slow as benefits managers get tough
A new analysis shows attempts by drugmakers to raise prices are being wiped out in negotiations with managers of drug insurance benefits like Express Scripts Holding Co. and CVS Health Corp.
More precise medical codes aim to track quality of care
On Oct. 1, the nation’s physicians and hospitals must start using a massive new coding system to describe your visit on insurance claims so they get paid.
Experimental osteoporosis drug bests Lilly’s Forteo in study
The experimental medicine, called romosozumab, showed better results than Eli Lilly and Co.’s Forteo after 12 months, Amgen and UCB said in a joint statement Wednesday.
Lilly wins patent ruling over blockbuster drug Alimta
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.
Lilly shares jump after positive study of diabetes drug
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
Indy medical device firm plans 125-job expansion
Catheter Research Inc.—which makes single-use medical devices, such as catheters—plans a $4.8 million expansion that will relocate its headquarters to larger space on the northwest side.
Lilly accused at trial of hiding Cymbalta ‘brain zap’ risk
The drugmaker faces as many as 5,000 cases claiming it downplayed Cymbalta’s withdrawal risks, which allegedly include electrical-shock sensations, vomiting and insomnia.